(NASDAQ: SGMO) Sangamo Therapeutics's forecast annual revenue growth rate of 9.49% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.47%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.24%.
Sangamo Therapeutics's revenue in 2025 is $63,756,000.On average, 2 Wall Street analysts forecast SGMO's revenue for 2025 to be $13,080,667,129, with the lowest SGMO revenue forecast at $4,849,873,018, and the highest SGMO revenue forecast at $21,311,461,241. On average, 2 Wall Street analysts forecast SGMO's revenue for 2026 to be $11,506,790,068, with the lowest SGMO revenue forecast at $2,308,353,023, and the highest SGMO revenue forecast at $20,705,227,114.
In 2027, SGMO is forecast to generate $27,327,169,118 in revenue, with the lowest revenue forecast at $16,508,221,618 and the highest revenue forecast at $38,146,116,619.